Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
14 stopped studies mapped to Head and Neck Carcinoma, Other and descendants · 100% state a reason
Over the 14 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00707473 | Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated… | Phase 2 | terminated | Jun 30, 2008 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors… | Phase 1 / Phase 2 | terminated | Nov 13, 2019 | Turning Point Therapeutics, Inc. | Adverse change in the risk/benefit. | Safety / toxicity |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated…(AcceleRET-MTC) | Phase 3 | withdrawn | Feb 18, 2021 | Hoffmann-La Roche | Due to several logistical challenges during start-up which could not be overcome study was… | Other (stated, no rule matched) |
| NCT02363647 | Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic… | N/A | terminated | Feb 16, 2015 | Icahn School of Medicine at Mount Sinai | No Current Funding | Funding |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | Phase 2 | withdrawn | Feb 12, 2019 | Antonio Fojo | Closed by sponsor | Other (stated, no rule matched) |
| NCT03630120 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | Phase 2 | terminated | Aug 14, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Lack of efficacy | Efficacy / futility |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced… | Phase 1 | terminated | Mar 3, 2016 | Merck Sharp & Dohme LLC | This study was terminated due to limited efficacy and not due to safety reasons. | Safety / toxicity |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Mar 16, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04116359 | Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment… | Phase 1 / Phase 2 | withdrawn | Oct 4, 2019 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or… | Phase 2 | withdrawn | Sep 27, 2019 | M.D. Anderson Cancer Center | No Participants Registered | Other (stated, no rule matched) |
| NCT00582712 | An Initial Study of Lithium in Patients With Medullary Thyroid Cancer | Phase 2 | terminated | Dec 28, 2007 | University of Wisconsin, Madison | Budget/Funding | Funding |
| NCT00923247 | A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome… | Phase 1 / Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Terminated due to slow accrual,primary endpoint reached \& investigator left NIH. | Investigator |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and… | Phase 1 | withdrawn | Jul 13, 2016 | Vanderbilt-Ingram Cancer Center | Loss of funding support | Funding |
| NCT01736878 | Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma(SUMMIT) | Phase 2 | withdrawn | Nov 29, 2012 | Eanm Research Ltd | Study was withdrawn due to unanticipated hassle in patient recruitment. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 17, 2026source: clinicaltrials